Abstract

At the present time, the majority of patients who develop Hodgkin's disease can be cured with radiotherapy and/or chemotherapy. A long follow up of cured patients has shown that the cumulative toxicity from treatment related complications rivals the mortality from Hodgkin's disease. In addition to late fatal complications, delayed adverse effects of therapy on the thyroid, reproductive system, and bones are burdens many patients have to bear. Future treatment regimens for Hodgkin's disease will be designed attempting to minimize these complications. Follow up of those patients now in remission should focus on the prevention of morbidity and mortality by anticipating and preventing late complications.

Original languageEnglish (US)
JournalAnnals of Oncology
Volume9
Issue numberSUPPL. 5
DOIs
StatePublished - Jan 1 1998

Fingerprint

Hodgkin Disease
Mortality
Therapeutics
Thyroid Gland
Radiotherapy
Morbidity
Bone and Bones
Drug Therapy

Keywords

  • Hodgkin's disease
  • Late toxicity
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Long-term toxicity of the treatment of Hodgkin's disease. / Armitage, James Olen.

In: Annals of Oncology, Vol. 9, No. SUPPL. 5, 01.01.1998.

Research output: Contribution to journalArticle

@article{44b19f7589d64a71b6f1286a07c80bba,
title = "Long-term toxicity of the treatment of Hodgkin's disease",
abstract = "At the present time, the majority of patients who develop Hodgkin's disease can be cured with radiotherapy and/or chemotherapy. A long follow up of cured patients has shown that the cumulative toxicity from treatment related complications rivals the mortality from Hodgkin's disease. In addition to late fatal complications, delayed adverse effects of therapy on the thyroid, reproductive system, and bones are burdens many patients have to bear. Future treatment regimens for Hodgkin's disease will be designed attempting to minimize these complications. Follow up of those patients now in remission should focus on the prevention of morbidity and mortality by anticipating and preventing late complications.",
keywords = "Hodgkin's disease, Late toxicity, Treatment",
author = "Armitage, {James Olen}",
year = "1998",
month = "1",
day = "1",
doi = "10.1093/annonc/9.suppl_5.S133",
language = "English (US)",
volume = "9",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Long-term toxicity of the treatment of Hodgkin's disease

AU - Armitage, James Olen

PY - 1998/1/1

Y1 - 1998/1/1

N2 - At the present time, the majority of patients who develop Hodgkin's disease can be cured with radiotherapy and/or chemotherapy. A long follow up of cured patients has shown that the cumulative toxicity from treatment related complications rivals the mortality from Hodgkin's disease. In addition to late fatal complications, delayed adverse effects of therapy on the thyroid, reproductive system, and bones are burdens many patients have to bear. Future treatment regimens for Hodgkin's disease will be designed attempting to minimize these complications. Follow up of those patients now in remission should focus on the prevention of morbidity and mortality by anticipating and preventing late complications.

AB - At the present time, the majority of patients who develop Hodgkin's disease can be cured with radiotherapy and/or chemotherapy. A long follow up of cured patients has shown that the cumulative toxicity from treatment related complications rivals the mortality from Hodgkin's disease. In addition to late fatal complications, delayed adverse effects of therapy on the thyroid, reproductive system, and bones are burdens many patients have to bear. Future treatment regimens for Hodgkin's disease will be designed attempting to minimize these complications. Follow up of those patients now in remission should focus on the prevention of morbidity and mortality by anticipating and preventing late complications.

KW - Hodgkin's disease

KW - Late toxicity

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0032457320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032457320&partnerID=8YFLogxK

U2 - 10.1093/annonc/9.suppl_5.S133

DO - 10.1093/annonc/9.suppl_5.S133

M3 - Article

C2 - 9926253

AN - SCOPUS:0032457320

VL - 9

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 5

ER -